Roche core operating income up 9% in Q2

This post was originally published on this site

Core operating income, which is adjusted for one-off effects, gained 9% to 12.67 billion Swiss francs ($13.07 billion), the Swiss drugmaker said in a statement on Thursday, above an analyst consensus of 12.1 billion francs.

It confirmed its full-year guidance.

($1 = 0.9694 Swiss francs)

Add Comment